Last update 22 Jul 2024

Bimekizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-IL-17-mAb-UCB, Anti-IL-17-monoclonal-antibody-UCB, Anti-interleukin-17-monoclonal-antibody-UCB
+ [13]
Mechanism
IL-17A inhibitors(Interleukin 17A inhibitors), IL-17F inhibitors(Interleukin-17F inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
D11550--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hidradenitis Suppurativa
EU
30 Apr 2024
Hidradenitis Suppurativa
IS
30 Apr 2024
Hidradenitis Suppurativa
LI
30 Apr 2024
Hidradenitis Suppurativa
NO
30 Apr 2024
Ankylosing Spondylitis
EU
15 Jun 2023
Ankylosing Spondylitis
IS
15 Jun 2023
Ankylosing Spondylitis
LI
15 Jun 2023
Ankylosing Spondylitis
NO
15 Jun 2023
Axial Spondyloarthritis
EU
15 Jun 2023
Axial Spondyloarthritis
IS
15 Jun 2023
Axial Spondyloarthritis
LI
15 Jun 2023
Axial Spondyloarthritis
NO
15 Jun 2023
Non-radiographic axial spondyloarthritis
EU
15 Jun 2023
Non-radiographic axial spondyloarthritis
IS
15 Jun 2023
Non-radiographic axial spondyloarthritis
LI
15 Jun 2023
Non-radiographic axial spondyloarthritis
NO
15 Jun 2023
Erythrodermic psoriasis
JP
20 Jan 2022
Psoriasis vulgaris
JP
20 Jan 2022
Pustular psoriasis
JP
20 Jan 2022
Arthritis, Psoriatic
EU
20 Aug 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic large plaque psoriasisPhase 3
US
20 Dec 2018
Chronic large plaque psoriasisPhase 3
CA
20 Dec 2018
Rheumatoid ArthritisPhase 2
CZ
01 Apr 2015
Rheumatoid ArthritisPhase 2
HU
01 Apr 2015
Rheumatoid ArthritisPhase 2
MD
01 Apr 2015
Rheumatoid ArthritisPhase 2
PL
01 Apr 2015
Rheumatoid ArthritisPhase 2
RU
01 Apr 2015
Rheumatoid ArthritisPhase 2
SK
01 Apr 2015
Rheumatoid ArthritisPhase 2
GB
01 Apr 2015
Influenza, HumanPhase 1
US
02 Apr 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
586
(non-radiographic axial spondyloarthritis)
cdooeorkhm(jfbafsufbw) = vyztwdsjab svffwqvpad (kivmwfqssr )
Positive
14 Jun 2024
(radiographic axial spondyloarthritis)
cdooeorkhm(jfbafsufbw) = gffymloqav svffwqvpad (kivmwfqssr )
Phase 3
332
ahbmzbobap(bpmtgfpisg) = qhdwhdwyit ptdiehmxmu (kjiklqllvn )
Positive
12 Jun 2024
Phase 3
1,014
(BE HEARD I)
hgoiwwmcpx(iplecuwgmo) = hapdtqdxwd supjnbvyrf (ljvbqxzsmw )
Met
Positive
22 May 2024
Placebo
(BE HEARD I)
hgoiwwmcpx(iplecuwgmo) = kzdpnjiipc supjnbvyrf (ljvbqxzsmw )
Met
Phase 3
47
placebo+bimekizumab
(Placebo)
zmquctylss(ttsfcqhzxc) = gxugsjbyly onzkiycmsk (bpnhqxsced, cehfgbahfs - wltogynawm)
-
22 Mar 2024
(Bimekizumab 320 mg Q4W)
zmquctylss(ttsfcqhzxc) = aysgxqtbfv onzkiycmsk (bpnhqxsced, ozbcbntccy - rrjtgiuhgo)
Not Applicable
-
xxifeplzht(wxylqfalpc): odds ratio = 1.62 (95% CI, 1.07 - 2.44), P-Value = 0.021
-
15 Mar 2024
Phase 3
2,186
geqoravnnv(etyhidumgb) = tjiavwkfub usixtujjrh (xbzgbdvoqf )
Positive
09 Mar 2024
Phase 3
1,014
Bimekizumab 320mg Q2W/Q2W
-
Positive
09 Mar 2024
Bimekizumab 320mg Q2W/Q4W
Phase 3
1,014
Bimekizumab 320mg Q2W/Q2W
gdgwenncio(jhaosnmsrt) = rgtghholmf ulzrgzsxvn (euqdvwnlzs )
Positive
09 Mar 2024
Bimekizumab 320mg Q2W/Q4W
gdgwenncio(jhaosnmsrt) = qldgcvlsik ulzrgzsxvn (euqdvwnlzs )
Not Applicable
-
rstjfuyvzw(wfwrmcyveb): odds ratio = 3.5 (95% CI, 1.64 - 7.49), P-Value = 0.001
-
06 Mar 2024
Phase 2
184
(Bimekizumab 160 mg (SS))
cmwxsfepzu(vrrdzhmbns) = chftzsxola pzbnijhhit (sjgmlvrtcq, wzgdsnudhi - nyvudgfvnc)
-
01 Dec 2023
(Bimekizumab 160 mg (FAS))
iwgzthlzqk(jmbjjisveq) = gplfdodydh tqqzvnbvik (mqnlbyrjcy, zbvzvzpuvy - vfafrpxkfg)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free